These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 22474287)

  • 1. Structure-activity analysis of niclosamide reveals potential role for cytoplasmic pH in control of mammalian target of rapamycin complex 1 (mTORC1) signaling.
    Fonseca BD; Diering GH; Bidinosti MA; Dalal K; Alain T; Balgi AD; Forestieri R; Nodwell M; Rajadurai CV; Gunaratnam C; Tee AR; Duong F; Andersen RJ; Orlowski J; Numata M; Sonenberg N; Roberge M
    J Biol Chem; 2012 May; 287(21):17530-17545. PubMed ID: 22474287
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Screen for chemical modulators of autophagy reveals novel therapeutic inhibitors of mTORC1 signaling.
    Balgi AD; Fonseca BD; Donohue E; Tsang TC; Lajoie P; Proud CG; Nabi IR; Roberge M
    PLoS One; 2009 Sep; 4(9):e7124. PubMed ID: 19771169
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The synergistic inhibition of breast cancer proliferation by combined treatment with 4EGI-1 and MK2206.
    Wang H; Huang F; Wang J; Wang P; Lv W; Hong L; Li S; Zhou J
    Cell Cycle; 2015; 14(2):232-42. PubMed ID: 25607647
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suppression of lysosome function induces autophagy via a feedback down-regulation of MTOR complex 1 (MTORC1) activity.
    Li M; Khambu B; Zhang H; Kang JH; Chen X; Chen D; Vollmer L; Liu PQ; Vogt A; Yin XM
    J Biol Chem; 2013 Dec; 288(50):35769-80. PubMed ID: 24174532
    [TBL] [Abstract][Full Text] [Related]  

  • 5. mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling.
    Rodrik-Outmezguine VS; Chandarlapaty S; Pagano NC; Poulikakos PI; Scaltriti M; Moskatel E; Baselga J; Guichard S; Rosen N
    Cancer Discov; 2011 Aug; 1(3):248-59. PubMed ID: 22140653
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CB2 cannabinoid receptors promote neural progenitor cell proliferation via mTORC1 signaling.
    Palazuelos J; Ortega Z; Díaz-Alonso J; Guzmán M; Galve-Roperh I
    J Biol Chem; 2012 Jan; 287(2):1198-209. PubMed ID: 22102284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Distinct signaling mechanisms of mTORC1 and mTORC2 in glioblastoma multiforme: a tale of two complexes.
    Jhanwar-Uniyal M; Gillick JL; Neil J; Tobias M; Thwing ZE; Murali R
    Adv Biol Regul; 2015 Jan; 57():64-74. PubMed ID: 25442674
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Focal Adhesion- and IGF1R-Dependent Survival and Migratory Pathways Mediate Tumor Resistance to mTORC1/2 Inhibition.
    Yoon SO; Shin S; Karreth FA; Buel GR; Jedrychowski MP; Plas DR; Dedhar S; Gygi SP; Roux PP; Dephoure N; Blenis J
    Mol Cell; 2017 Aug; 67(3):512-527.e4. PubMed ID: 28757207
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Niclosamide, an old antihelminthic agent, demonstrates antitumor activity by blocking multiple signaling pathways of cancer stem cells.
    Pan JX; Ding K; Wang CY
    Chin J Cancer; 2012 Apr; 31(4):178-84. PubMed ID: 22237038
    [TBL] [Abstract][Full Text] [Related]  

  • 10. mTORC1 inhibition and ECM-cell adhesion-independent drug resistance via PI3K-AKT and PI3K-RAS-MAPK feedback loops.
    Galoian K; Temple HT; Galoyan A
    Tumour Biol; 2012 Jun; 33(3):885-90. PubMed ID: 22246604
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacological inhibition of mTORC1 prevents over-activation of the primordial follicle pool in response to elevated PI3K signaling.
    Adhikari D; Risal S; Liu K; Shen Y
    PLoS One; 2013; 8(1):e53810. PubMed ID: 23326514
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Niclosamide prevents the formation of large ubiquitin-containing aggregates caused by proteasome inhibition.
    Gies E; Wilde I; Winget JM; Brack M; Rotblat B; Novoa CA; Balgi AD; Sorensen PH; Roberge M; Mayor T
    PLoS One; 2010 Dec; 5(12):e14410. PubMed ID: 21203451
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A dual mTORC1 and mTORC2 inhibitor shows antitumor activity in esophageal squamous cell carcinoma cells and sensitizes them to cisplatin.
    Huang Y; Xi Q; Chen Y; Wang J; Peng P; Xia S; Yu S
    Anticancer Drugs; 2013 Oct; 24(9):889-98. PubMed ID: 23838676
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Serum and glucocorticoid-regulated kinase 1 (SGK1) activation in breast cancer: requirement for mTORC1 activity associates with ER-alpha expression.
    Hall BA; Kim TY; Skor MN; Conzen SD
    Breast Cancer Res Treat; 2012 Sep; 135(2):469-79. PubMed ID: 22842983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulation of mTORC1 signaling by pH.
    Balgi AD; Diering GH; Donohue E; Lam KK; Fonseca BD; Zimmerman C; Numata M; Roberge M
    PLoS One; 2011; 6(6):e21549. PubMed ID: 21738705
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Potentiation of Growth Inhibitory Responses of the mTOR Inhibitor Everolimus by Dual mTORC1/2 Inhibitors in Cultured Breast Cancer Cell Lines.
    Leung EY; Askarian-Amiri M; Finlay GJ; Rewcastle GW; Baguley BC
    PLoS One; 2015; 10(7):e0131400. PubMed ID: 26148118
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting of mTORC2 prevents cell migration and promotes apoptosis in breast cancer.
    Li H; Lin J; Wang X; Yao G; Wang L; Zheng H; Yang C; Jia C; Liu A; Bai X
    Breast Cancer Res Treat; 2012 Aug; 134(3):1057-66. PubMed ID: 22476852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic sensitivity to Rac GTPase inhibition requires consequential suppression of mTORC1, AKT, and MEK signaling in breast cancer.
    Hampsch RA; Shee K; Bates D; Lewis LD; Désiré L; Leblond B; Demidenko E; Stefan K; Huang YH; Miller TW
    Oncotarget; 2017 Mar; 8(13):21806-21817. PubMed ID: 28423521
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhancing mammalian target of rapamycin (mTOR)-targeted cancer therapy by preventing mTOR/raptor inhibition-initiated, mTOR/rictor-independent Akt activation.
    Wang X; Yue P; Kim YA; Fu H; Khuri FR; Sun SY
    Cancer Res; 2008 Sep; 68(18):7409-18. PubMed ID: 18794129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. AZD2014, an Inhibitor of mTORC1 and mTORC2, Is Highly Effective in ER+ Breast Cancer When Administered Using Intermittent or Continuous Schedules.
    Guichard SM; Curwen J; Bihani T; D'Cruz CM; Yates JW; Grondine M; Howard Z; Davies BR; Bigley G; Klinowska T; Pike KG; Pass M; Chresta CM; Polanska UM; McEwen R; Delpuech O; Green S; Cosulich SC
    Mol Cancer Ther; 2015 Nov; 14(11):2508-18. PubMed ID: 26358751
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.